Genscript Biotech Corporation

Hey, and thank you for standing by. Welcome to GNScript Biotech 2025 Interim Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star 1 and 1 on your telephone keypad. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one and one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, CFO Josie Zhao. Please go ahead.

Hello, everyone. This is Josie Zhao, Interim CFO at SyncQuib. Welcome to our 2025 Interim Resource Conference call. Joining me on the call today are Mr. Robin Meng Chairman of the Board Ms. Sherry Shao, rotating CEO of Dynscript Dr. Rui Cheng, President of Dynscript Life Science Group Dr. Ai Xibai, General Manager of BestScience Mr. Alan Guo, CEO of Probire During today's call, we will be making statements about future expectations, plans, and prospects, as well as any other space regarding matters that are not historic facts, which may constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements because of various important risk effects and changing market conditions. We do not undertake any obligation to publicly update any forward-looking statements. Today, Sherry will start with a company overview and our business heads will present the first half highlights for each segment. I will then guide you through the financial performance. Following that, Sherry will update our four-year guidance and the second half business focus. We also have a Q&A section at the end of the call. As a reminder, today's presentation materials can be accessed in the investor relations section of the company website. Now I will hand over to Sherry.

Thank you, Juicy, and thanks to everyone for your ongoing support for Gensquad Group. In the first half, Gensquad Group delivered rapid growth despite the complex geopolitical environment. The group's revenue grew about 82% year-over-year. The adjusted profit from continuing operations grow significantly to approximately 180 million US dollars. Turning to each segment, our transcript life science business continues to deliver steady growth, excluding the impact of the collaboration with Lenovo for biobiological CDMO business, the party returned to revenue growth after the industry headwind. Back then, our industrial synthetic biology segment continued its industry-leading growth trajectory. For our associate company, Legion Biotech, its best-in-class CAR-T product, CARVICT, has treated over 7,500 patients. In second quarter, CARVICT made trace cells grow 136% to $439 million, making it the strongest CAR-T launch to date. In the US, more than half of its utilization is in the earlier line setting. Legend anticipates achieving operational breakeven for CAR-VT by the end of 2025 and company-wide profitability by 2026, excluding unrealized foreign exchange gains or losses. We believe Legends' improved financial performance will benefit the group's profitability in the long run. By the end of the first half, Jansport Group has a global workforce of over 5,700 members. Our global footprint is expanding rapidly. Due to automation and digitalization, our manufacturing-related employees have decreased. However, we have expanded our R&D teams to enhance our leading position in the industry. As of the first half, the group's cash position stood at $970 million, funding our global expansion, R&D progress, and capacity ramp up. Before we dive into the business part, let me share an update on our impressive sustainability achievements. In recent years, ESG has emerged as the gold standard for global corporate competitiveness. In the first half, Our significant breakthroughs across global ESG ratings brought us to a leading position, including the silver medal from Ecovadis. The MSCI ESG rating upgraded to AA, standard and poor global CSIS score elevated to the industry top 7%, and inclusion in the FTSE4 Good Index series. As a result of years of strategic investment and continuous improvement, these achievements highlight our ability to meet the evolving expectations of our clients and investors. We are also broadening our reach within the global sustainability community by being part of the United Nations global compact and the Science-Based Target Initiative and a supplier partner of the Pharmaceutical Supply Chain Initiative . In our operations, our ESG practices have contributed to financial savings through improved operational efficiency. Our strong ESG performance has resonated positively with our stakeholders by helping our clients meet their goals and driving value creation for shareholders. Among others, I'd like to highlight data security as part of our governance practices. All of our 16 global operating entities have been certified to ISO 27001 for information security, ensuring the highest international standards in data security and IP protection. As we look ahead, we remain dedicated to advancing our ESG initiatives, further strengthening our competitive edge and contributing to a more sustainable future. Now, I would like to invited leaders from each segment to present the highlights from the first half of the year. We will begin with Dr. Rui Chen from the Genscript Life Science Group.